MS) were performed according to a protocol that described strict positioning techniques, an acceptable range of scanning parameters, and the content and format required for films and computer tapes to be sent to the University of British Columbia (UBC) MS/MRI Analysis Group. The MS/MRI Analysis Group provided feedback about
the quality of scans and consistency of scanning technique. Each center used external and internal landmarks specific to its scanner to duplicate the same imaging plane and patient position in subsequent studies. T1-weighted scans (repetition time 500-600 msec, echo time <25 msec) with the same scan plane, thickness, and position as PD/T2 scans (5 mm transverse contiguous [or minimal interslice <1 mm] slices obtained from the foramen magnum to the vertex) were obtained before and 5 minutes after intravenous (IV) administration of 0.1 mmol/kg gadolinium. The same positioning, imaging sequences, and parameters were used for all subsequent scans. Scan data were read, converted, and stored on the MS/MRI Analysis Group's computer (the group had no knowledge of patients' treatment and outcomes). Films and tapes were checked for completeness, consistency, and compliance with the scanning protocol; those deemed unsatisfactory were rejected, and urgent replacement scans were requested. Baseline scans obtained 1 month and within 48 hours before treatment initiation and monthly on-treatment scans were reviewed in chronologic order.
Enhancing lesions were identified and assigned T1-Gd identification numbers, which were recorded in a database. Newly enhancing T1 lesions were those that had never enhanced before. sc IFN β-1a vs placebo, 44% reduction; p=0.073 b
Supplementary Table 1. Patient demographics and baseline characteristics from patients in PRISMS with and without newly enhancing lesions (n=196).
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